Five Life Sciences Projects Receive Funding
The Life Sciences Fund is providing funding to five projects across Alberta, British Columbia and Ontario.
Applied Pharmaceutical Innovation in Alberta will receive up to $21.9 million toward a $23.5 million initiative focused on antimicrobial supply resilience. The project aims to help secure broad-spectrum antibiotics and other antimicrobial drugs for priority pathogens, antimicrobial-resistant threats and combat-related infections.
Avivo Biomedical in British Columbia will receive up to $10.9 million toward a $33.9 million project focused on expanding blood transfusion and organ transplant capabilities. Its technology is designed to convert different blood types into Type O, including O negative.
Northern RNA in Alberta will receive up to $6 million toward a $9.5 million project establishing good manufacturing practice capacity for oligonucleotides and self-amplifying RNA. These technologies have applications in vaccines, therapeutics and diagnostics.
Qidni Labs in Ontario will receive up to $12.5 million toward a $25 million project to finalize the design of portable and nearly waterless hemodialysis systems. The project includes pilot-scale manufacturing in Ontario, clinical studies and the collection of real-world battlefield data.
STEMCELL Technologies in British Columbia will receive up to $2.8 million toward a $2.9 million project to establish domestic manufacturing capacity for custom cell-culture media. The initiative is intended to strengthen biomanufacturing resilience and reduce reliance on foreign supply chains.
More Funding for Canada’s Health Security
The Life Sciences Fund is also providing $1.55 million over three years to each of five pan-Canadian research hubs.
The funding will extend existing pandemic-preparedness activities and support the development of dual-use technologies.
These investments are intended to strengthen Canada's scientific and industrial capabilities while supporting preparedness for future health challenges.
New Drug Shortage Monitoring Initiative
Additional funding will support the creation of the Canadian Drug Supply Observatory.
Dr. Mina Tadrous of the University of Toronto will receive $2.2 million to establish the national hub, which will monitor, analyze and respond to drug shortages.
The initiative is designed to provide a more coordinated approach to understanding medicine supply problems and supporting responses when shortages occur.
Canadian Biobank Infrastructure Also Gets Support
The Canadian Biobank Alliance, housed at the Ottawa Hospital Research Institute, will receive $1.2 million.
The funding will be used to maintain and upgrade a Canadian biobank data platform connecting academia, government and industry.
The platform connects academia, government and industry.
Additional Funding for Vaccine Manufacturing
The Ottawa Hospital Research Institute and Boreal Biomanufacturing will receive $880,000 to expand adenovirus manufacturing capacity and capabilities.
According to the federal government, the project will support larger-scale production and commercialization of vaccines and therapies. It will also introduce an electronic quality management system designed to strengthen operational efficiency.
The funding is part of the government's broader effort to strengthen domestic biomanufacturing capacity.
Needle-Free Vaccine Platform Gets Funding
Dr. Matthew Miller of McMaster University will receive $780,000 to advance a needle-free inhaled vaccine platform.
The project will focus on improving the platform's flexibility and adaptability for different pathogens.
The funded project is focused on advancing the platform.
Why Canada Is Investing in Life Sciences
The federal government says the Life Sciences Fund is designed to strengthen scientific, technological and industrial capabilities in Canada's life sciences sector.
The fund is delivered through Health Emergency Readiness Canada and is intended to support national defence, national security and economic prosperity.
The projects announced on September 18 also include funding connected to Canada's Defence Industrial Strategy. The strategy aims to strengthen Canada's domestic defence industrial base, support sovereign and dual-use technologies, reinforce supply chains and encourage innovation.
Building More Domestic Health Capacity
The latest investment covers several areas of Canada's health and life sciences ecosystem, from antimicrobial medicines and blood technology to RNA manufacturing, dialysis equipment, biomanufacturing and vaccine research.
The government says these investments will help strengthen Canada's health security and domestic industrial capabilities.
For the companies, universities and research organisations receiving support, the funding will contribute to projects ranging from manufacturing infrastructure to research platforms and health technology development.
What Happens Next?
The funded projects will move forward across different areas of life sciences and health technology.
Some initiatives are focused on manufacturing capacity, while others involve clinical studies, research infrastructure, drug-shortage monitoring or technology development.
The government says the broader objective is to develop a robust and competitive Canadian life sciences ecosystem while improving resilience and domestic capabilities.
Bottom Line
Canada has announced $67 million through its Life Sciences Fund for projects aimed at strengthening health resilience, domestic manufacturing and dual-use life sciences capabilities.
The funding covers antimicrobial supply, blood and transplant technology, RNA manufacturing, portable dialysis, cell-culture media and additional initiatives involving drug shortages, biobanks, vaccine manufacturing and needle-free vaccine technology.